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RESUMO 
 
O défice da desoxiguanosina cinase (dGUOK), causado por mutações no gene 
DGUOK, leva ao desenvolvimento da forma hepatocerebral da Síndrome de depleção de 
DNA mitocondrial (MDS), ligadas a uma redução drástica no número de cópias do genoma 
mitocondrial (mtDNA), associada a elevada mortalidade e sem estratégias terapêuticas 
disponíveis, na criança.  
Apesar de se terem vindo a identificar novas mutações no gene DGUOK ao longo dos 
últimos anos, uma correlação genótipo-fenótipo precisa e exequível, nunca foi estabelecida. 
Um padrão reprodutível de associação entre o tipo e localização das mutações genéticas no 
gene DGUOK e a clínica apresentada pelo doente facultaria aos clínicos a capacidade de 
estimar, num estádio neonatal, ou mesmo pré-natal, o diagnóstico e a gravidade da doença, 
provendo os clínicos com ferramentas mais racionais para aconselhamento genético adequado 
às famílias e aos futuros pais. 
Procedeu-se a uma busca extensiva na base de dados de referências MEDLINE para 
procurar todas as mutações no gene DGUOK, publicadas até à data. Estas alterações foram 
analisadas quanto à sua localização no gene e o seu impacto na função e estrutura da proteína, 
assim como nas manifestações clínicas apresentadas pelos doentes e foi efetuado um estudo 
da correlação genótipo-fenótipo. 
Verificou-se a inexistência de uma correlação genótipo-fenótipo precisa e clara em 
doentes com MDS causado por mutações no gene DGUOK, revelando a existência de 
mecanismos mais complexos e ainda desconhecidos, que estarão subjacentes ao início e à 
progressão da doença. 
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LIST OF ABBREVIATIONS 
 
ADP Adenosine diphosphate 
ALT Alanine transaminase 
AST Aspartate transaminase 
ATP Adenosine triphosphate 
c. Coding DNA sequence 
cDNA Complementary DNA 
C10orf2 Chromosome 10 open reading frame 2 
dCK Deoxycytidine kinase 
DGUOK/ dGK Deoxyguanosine kinase 
DGUOK Gene coding for dGK 
DNA Deoxyribonucleic acid 
dNDP Deoxyribonucleotide diphosphate 
dNMP Deoxyribonucleotide monophosphate 
dNTP Deoxinucleotides triphosphate 
dup Duplication 
GGT Gamma-glutamyl transpeptidase 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
MDS Mitochondrial DNA Depletion Syndromes 
MpV17 MpV17 Mitochondrial Inner Membrane Protein 
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MPV17 Gene coding for MpV17 Mitochondrial Inner Membrane Protein 
MRC Mitochondrial Respiratory Chain 
mtDNA mitochondrial DNA 
p. protein sequence 
POLG Polymerase (DNA directed), gamma 
POLG Gene coding for Polymerase (DNA directed), gamma 
RNA Ribonucleic acid 
RRM2B Ribonucleotide Reductase M2 B (TP53 Inducible) 
SUCLG1 Succinate-CoA Ligase, Alpha Subunit 
SIFT Sorting Intolerant From Tolerant 
SUCLA2 Succinate-CoA Ligase, ADP-Forming, Beta Subunit 
TK1 Thymidine kinase 1 
TK2 Thymidine kinase 2 
TYMP Thymidine Phosphorylase 
5'-dRP  5'-deoxyribose-5-phosphate 
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ABSTRACT 
 
Deoxyguanosine kinase (coded by DGUOK) deficiency, caused by DGUOK gene 
mutations, leads to development of the hepatocerebral form of mitochondrial DNA depletion 
syndrome (MDS), linked to mitochondrial genome (mtDNA) copy number severe decline, 
associated to high mortality and absence of available therapeutic strategies in infants. 
In spite of the continuous identification of new DGUOK mutations over the years, an 
accurate and feasible genotype-phenotype correlation in DGUOK patients is lacking. A 
reproducible pattern of association between the type and localization of DGUOK gene 
mutation and its effect on patients´ clinic would ground physicians with the capacity to 
foresee, at a neonatal or even pre-natal stage, the disease diagnostics and severity, providing 
the clinicians, therefore, with more rationale tools for adequate genetic counselling in families 
and future parents.  
An extensive search on MEDLINE database was performed in order to search for all 
published DGUOK gene mutations to date. These alterations were analysed for their 
localization in the gene and their impact on protein structure and function and the clinical 
manifestations and a genotype-phenotype correlation study has been carried out.  
It was evident the absence of a clear and accurate genotype-phenotype correlation in 
patients with MDS caused by DGUOK mutations, unmasking, likely, more complex and 
unknown mechanisms underlying disease onset and progression. 
 
Keywords: Deoxyguanosine Kinase, DGUOK gene mutations, mitochondrial DNA 
depletion syndrome, MDS, hepatocerebral form, hepatic form. 
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INTRODUCTION 
 
Aerobic organisms require energy for their metabolic activities. In eukaryotes, the 
main source of energy comes from ATP, the end-product of oxidative phosphorylation, a 
cascade of electron-transfer reactions taking place at the inner mitochondrial membrane, 
through the mitochondrial respiratory chain (MRC) proteins and transporters [1]. 
Only a minority of the MRC complexes subunits are encoded by mitochondrial DNA 
(mtDNA), and thus most of the key catalytic components of these electron carriers are nuclear 
encoded [2]. The mtDNA encodes for a total of 37 genes, 13 of which correspond to subunits 
of the MRC complexes I (n=7), III (n=1) and IV (n=3) and complex V - ATP synthase (n=2). 
The remaining 24 genes encode for ribosomal RNA (n=2) and transfer RNA (n=22), required 
for mtDNA encoded MRC subunits synthesis. Conversely, all the proteins involved in 
mtDNA biogenesis, replication and maintenance are encoded in the nuclear genome. At least 
approximately 1,500 nuclear genes are known to be involved in these processes [3].  
Defects in either genomes, nuclear or mitochondrial, can cause MRC disorders. In the 
past two decades a group of autosomal recessive, phenotypically heterogeneous disorders, 
with Mendelian transmission [4], have been extensively reported in association with the same 
feature, a significant reduction in mtDNA copy number, which is known as mtDNA 
depletion.  
 
MITOCHONDRIAL DEPLETION SYNDROMES 
 
Mitochondrial depletion syndrome (MDS) comprise a group of autosomal recessive 
disorders characterized by a severe reduction of mtDNA content (<30%), caused by mutations 
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in the nuclear-encoded proteins involved in mtDNA synthesis and maintenance [4]. These 
proteins include POLG, C10orf2, SUCLG1, SUCLA2, TYMP, RRM2B, MPV17, DGUOK 
and TK2 [2, 5]. No mtDNA point mutations or rearrangements (deletions, insertions) in MDS 
patients have been reported to date. 
Tissue-specific mtDNA depletion is a particularity of MDS disorders. Although both 
DGUOK and TK2 genes encode enzymes belonging to the nucleoside salvage pathway in the 
mitochondria, mutations in the first result in marked mtDNA depletion in the liver and, in 
most cases, in the brain [6, 7], while TK2 deficiency is characterized by a severe mtDNA 
reduction in skeletal muscles [8, 9]. Since mtDNA encodes for a only 13 MRC subunits, the 
activity of all complexes but the pan-nuclear encoded complex II, are markedly decreased in 
MDS affected tissues [6]. 
MDS frequently manifest soon after birth [10]. In fact, the mtDNA amount almost 
doubles, within the first year of life, suggesting a higher demand on mtDNA synthesis, related 
to the aerobic respiration and high rate of tissue grow, after birth [11]. 
Resulting from its molecular heterogeneity, clinical characteristics of MDS patients 
vary within a high range, but can be divided in three presenting categories: myophathic, 
hepatocerebral and encephalomyophatic [2, 12].  
 
MITOCHONDRIAL NUCLEOTIDE METABOLISM AND mtDNA 
REPLICATION 
 
Mitochondrial DNA replication seems to occur independently of cell-division cycle, 
although some studies have argued that this is not always the case [13, 14]. Additionally, if 
both nuclear and mitochondrial genomes encoded proteins are needed for functional 
mitochondria, it is not logical to think that both mtDNA replication and cell cycle are 
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independent from each other. An elementary replication complex formed by the 
mitochondrial helicase Twinkle, the mitochondrial single stranded DNA-binding protein and 
the DNA polymerase gamma, are responsible for mtDNA replication and repair. Concerning 
repair, enzyme activities of DNA polymerase, 3´-5´ Exonuclease and 5´ dRP lyase [15, 16] 
play an essential role, in addition to DNA synthesis [17]. 
Previous studies have demonstrated that mtDNA replication is completed in 
approximately 1 to 2 hours [18] and an adequate and balanced pool of deoxinucleotides 
triphosphate (dNTP) in the mitochondrion matrix is required for this process to be efficient. 
Evidence is lacking supporting de novo synthesis of dexynucleotides in mitochondria, 
so they probably must be imported from the cytosol. There are two major DNA precursor 
metabolic routes. The first consists on the salvage of extracellular nucleotides that cross the 
plasmatic membrane via a membrane nucleoside transporter. Once inside the cell, cytosolic 
kinases add inorganic phosphate to the 5´position of nucleosides, trapping them in the cell. 
Cytosolic deoxycytidine kinase (dCK) has substrate specificity for deoxyadenosine and 
deoxyguanosine, as well as for deoxycytidine, while TK1 catalyzes the phosphorylation of 
thymidine to deoxythymidine monophosphate. Monophosphate nucleosides are then 
converted into di- and triphosphate nucleosides by nucleoside mono- and diphosphate kinases, 
respectively [19, 20]. 
The second and major route for dNTP synthesis is catalyzed by a cytoplasmic 
ribonucleotide reductase, which reduces ribonucleotide diphosphate into deoxyribonucleotide 
diphosphate (dNDP) [21]. The dNDPs are then converted to dNTPs by a nucleoside 
diphosphate kinase. 
Due to mitochondrial inner membrane impermeability to charged molecules, cytosolic 
deoxiribonucletides, deoxyribonucleotide monophosphate (dNMP), dNDP and dNTP are 
actively transported into the mitochondria through specialized mitochondrial deoxynucleotide 
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carriers. In yeast, an ATP/ADP exchanger, the GTP/GDP carrier Ggc1p and deoxynucleotide 
carrier Rim2p were described [22, 23]. By homology, SLC25A33 and SLC25A36 were 
suggested as mitochondrial deoxynucleotide transporters in humans [24]; however, only the 
first was confirmed and named as PNC1 [25, 26]. More recently, Drim2 was functionally 
characterized in Drosophila melanogaster [27]. 
The salvage pathway of deoxynucleotides synthesis inside the mitochondria is assured 
by two mitochondrial kinases: DGUOK, having substrate specificity for purine 
deoxynucleotides [28], and TK2, which phosphorylates pyrimidine deoxynucleotides [29]. 
Deoxinucleotide diphosphates are finally converted into dNTPs through the activity of 
mitochondrial nucleotide-diphosphate kinases. 
Of important note, a computational study demonstrated that supply of dNTPs, by the 
mitochondrial salvage pathway, cover only one third of dNTPs needed for mtDNA 
replication, and therefore, an external source of deoxynucleotides would be necessary [18]. 
Further investigation is required to demonstrate which other sources account for a balanced 
dNTP pool in the mitochondria. 
 
THE MITOCHONDRIAL SALVAGE ENZYME DGUOK 
 
Mutations affecting genes coding for mitochondrial deoxynucleotide metabolism 
enzymes, such as TK2 and DGUOK, are known causes of mitochondrial depletion 
syndromes. Up to date, over 40 mutations in DGUOK gene associated with MDS have been 
described. 
Human DGUOK nuclear gene is located in the short arm of chromosome 2 (2p13.1) 
and it was first identified by Johansson and colleagues [28] through dCK cDNA homology 
studies. Since then, two different isoforms for DGUOK have been described.  
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DGUOK is ubiquitously expressed in all tissues, with higher levels in muscle, liver, brain and 
lymphoid tissues [28, 30]. It harbours a mitochondrial translocation signal, guiding the protein 
into the organelle, in which it exerts its function. Post-translocation cleavage at a putative 
mitochondrial peptidase cleavage site processes the enzyme into its mature form [28, 30]. 
Enzymatic activity studies revealed that DGUOK phosphorylates deoxy-guanosine, deoxy-
inosine and deoxy-adenosine units in the mitochondrion [28]. Complementarily, 
phosphorylation of purine deoxy-nucleotides in the cytoplasm is carried out by dCK enzyme.  
DGUOK protein is composed by 277 aminoacids. Several studies have accounted to 
identify, in the protein, the motifs and sites important for its structure and enzymatic function. 
A mitochondrial translocation signal has been allocated to the first 39 aminoacids [28]. 
Furthermore, the phosphate donor (ATP) binds to aminoacids 45 to 53 and 206 to 208, as 
inferred from electronic annotation (Source: UniProt). In turn, deoxynucleotides interact with 
the isolated aminoacids 70, 100, 111, 118, 142, 147, 151 and 211 in the enzymatic pocket. 
Finally, the glutamic acid at position 141 (NP_550438), functions as a proton acceptor.  
 
CLINICAL FEATURES IN PATIENTS WTH DGUOK DEFICIENCY 
 
DGUOK deficiency presents as an infantile onset MDS with a very heterogeneous 
clinical phenotype and is transmitted as an autosomal recessive trait or, more frequently, as 
extensively reported, as a compound heterozygous disorder [4].  
The more severe phenotype associated to DGUOK deficiency is the hepatocerebral 
and affects mostly neonates; patients usually die before 2 years of age [31-33]. The hepatic 
form is clinically milder and is characterized by acute liver failure without neurological 
impairment, associated to longer life expectancy (infancy or even adulthood) [32, 34-37]. 
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Hepatocerebral form 
 
Patients with the hepatocerebral form of MDS present with nystagmus, hypotonia and 
psychomotor retardation, commonly before 8 months of age. Associated with these 
neurological symptoms, patients invariably develop progressive liver failure [31, 33, 35, 38-
43]. Elevated hepatic alanine (ALT) and aspartate aminotransferases (AST) as well as 
gamma-glutamyl transpeptidase (GGT) are, in most of the cases, a warning for cytolysis and 
cholestasis. Over half of the patients present with hepatomegaly, jaundice, coagulopathy and/ 
or hypoglycaemia, and a few are diagnosed with cirrhosis. Blood sampling commonly shows 
lactic acidemia, hiperaminoacidemia (mostly tyrosinemia), low levels of glucose and 
increased levels of bilirrubin. Most patients present very high levels of ferritin and alpha 
fetoprotein and differential diagnosis with neonatal hemochromatosis must be considered [7, 
34, 38, 39, 41-47].  
Disease frequently evolves from progressive cholestasis and cytolysis to fatal liver 
failure. Concomitantly, patients typically develop neurological features, commonly 
accompanied by failure to thrive. Other systemic manifestations, such as renal tubulopathy, 
cardiomiopathy or malabsorption, related to pancreatic insufficiency, may be observed [38, 
43]. The presence of neurologic manifestations precludes liver transplantation [35]. 
 
Hepatic form   
 
Hepatic form presents with isolated liver disease [32, 34-37, 47]. Liver failure clinical 
features are similar to those presented by the hepatocerebral patients. 
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DGUOK MUTATIONS 
 
An extensive MEDLINE search, using the key words “DGUOK”, “dGK”, “DGUOK 
mutation”, “mitochondrial depletion syndrome” and “hepatocerebral” was carried out to 
allocate all case reports on DGUOK mutations/deficiency published to date. Reported 
mutations in the DGUOK gene found through this search are gathered in Tables 1 and 2. 
DGUOK related MDS patients carry either homozygous or compound heterozygous 
mutations. Missense mutations are, by far, the most common type of DGUOK gene variant in 
patients, followed by nonsense and deletion mutations (tables 1 and 2). Gene mutations 
altering splice sites or insertions have also been described as pathological (tables 1 and 2). 
The most frequent mutation found in patients is a GATT duplication between nucleotides 763 
and 766 in exon 6, resulting in a frameshift and a premature stop codon, translating into a 
truncated protein of 255 aminoacids [7, 36, 37, 39, 43, 48].   
It is our aim to establish a correlation between the type, as well as the site, of the 
mutation in the gene and consequent alteration in the protein chain and phenotype 
(hepatocerebral or hepatic) observed. No stringent genotype-phenotype correlation seems to 
exist. Although one should expect that severe phenotypes would correspond to mutations in 
structurally and functionally conserved regions, hepatocerebral as well as hepatic phenotypes 
are observed in patients with mutations in substrate binding sites or signal peptides in the 
DGUOK protein chain. In addition, although some patients with isolated hepatic failure 
harbour homozygous mutations that changes aminoacids thought to be expendable for 
substrate binding (p.S107P, p.Y191C, p.D255Y), there are two hepatic patients carrying 
mutations in the coding gene for ATP nucleotide binding site 46 and in the translation 
initiating AUG codon, respectively (Table 1). Strikingly, this last variant, in which the 
initiation methionine is replaced by a threonine (c.2T>C), has also been described in a 
hepatocerebral patient (Table 1). Such observations confirm the non existence of a pattern for 
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disease severity prediction. A contribution of other unknown factors, genetic or not, for the 
observed disease phenotype, is possible. 
Patients carrying missense variants, either in homozygosity or compound 
heterozygozity, present with the hepatic form, associating this type of mutation to a milder 
phenotype. On the other hand, patients harbouring duplications, deletions, insertions or splice 
site mutations invariably develop neurological features (Tables 1 and 2). One hypothesis for 
this trend is that the latest types of mutations cause dramatic changes to the protein chain, 
such as alteration of splicing site or frameshift with premature termination codon, which 
determines its non functionality. Filosto and colleagues reported the homozygous 
c.763_766dupGATT mutation in a patient who died at 31 months of age from liver failure and 
gastrointestinal complications [48]. The patient developed neurological symptoms, namely 
unsteady gait and limb ataxia [48]. In contrast to others opinion [49], this should be 
considered a hepatocerebral patient. 
Compound heterozygous mutations are slightly more frequent in isolated hepatic form 
of MDS than in the hepatocerebral form (Table 2). Interestingly, for all DGUOK compound 
heterozygous mutations in hepatic patients reported to date, both or at least one of the allelic 
alterations have never been associated to a severe hepatocerebral phenotype. It is relevant to 
notice that, in four out of the seven heterozygous patients with hepatic phenotype (Table 2), 
one of the allelic variants has been described, when occurring in both alleles, in association to 
hepatic and cerebral symptoms. For the other three compound heterozygous patients, none of 
the mutations have so far been described to be causative of disease in homozygosity. These 
observations may indicate that, for missense compound heterozygous mutations, the presence 
of a non deleterious mutation (e.g. not associated, to date, with hepatocerebral form in 
homozygous patients) limits the phenotype to the liver, precluding the development of 
neurological features. Accordingly, a patient carrying the compound heterozygous mutation 
Duarte S., 2014 
 
14 
 
p.[Y191C];[K51Q] has been diagnosed with hepatocerebral form of MDS [7]. Since 
homozygous p.Y191C has been described as hepatic form of MDS, and has never been found 
in hepatocerebral patients, one could anticipate that p.K51Q in homozigosity should cause a 
hepatocerebral phenotype. 
Siblings harbouring the compound heterozygous mutation p.[L250S];[M1?] have been 
identified [34]. Both mutations have been described to generate a hepatocerebral phenotype in 
homozygosity. Hence, both siblings would be expected to develop neurological features. 
However, one of the siblings showed only liver symptoms and was alive at the time of the 
report (5 months old), while the other sibling died at 9 months of life. It is plausible to 
consider that there is a time lag for the neurological symptoms to appear in MDS patients and 
that such features had not developed in both children at the time of the report or death, 
respectively. Also, intrafamiliar variability (expressivity, for example) may determine the 
disease severity [34].  
Freisinger and his team reported a monoallelic heterozygous patient presenting with a 
hepatocerebral phenotype (Table 2) whose DNA sequencing disclosed a missense mutation at 
codon 170, resulting in a glutamine to arginine substitution. In spite of the neurological 
symptoms, the patient was alive (3 months of age) at the time of the report [34]. Previous 
studies have detected the p.Q170R variant in approximately 2% of control individuals [50] 
and SIFT analysis evaluates this gene modification as non deleterious as it has been reported 
in the dbSNP database (http://www.ncbi.nlm.nih.gov/ projects/SNP/) [50], supporting that 
Q170R variant is a polymorphism rather than a pathogenic mutation. Nevertheless, the same 
type of analysis on PolyPhen-2 suggests that Q170R variant affects the structure and function 
of DGUOK [50]. Thus, the reason why this patient developed a hepatocerebral phenotype 
remains unclear. A second mutation or even exonic deletion causing the disease cannot be 
disregarded [34].  
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DNA sequencing is widely used for clinical diagnosis of human mutations, but often 
does not detect intragenic deletions or duplications. The approach by using oligonucletide 
array-based comparative genomic hybridization, a targeted library of genes involved in 
mitochondria biogenesis and function, has been recently demonstrated to be particularly 
helpful as a complementary technique for the identification of whole gene deletions or large 
intragenic deletions, in MDS and mtDNA related disorders [51, 52]. 
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Table 1. Homozygous mutations in the DGUOK gene associated with hepatocerebral and hepatic forms of MDS. 
Mutation Location 
Exon/ Intron 
Effect Clinical 
Phenotype 
Survival Reference 
c.3G>A 
 
 
1 p.M1? Hepatocerebral 18 mo 
 
 
[39] 
c.2T>C 
 
1 p.M1? Hepatocerebral 
Hepatic 
3 mo 
3 mo 
 
[31] 
[32] 
c.34C>T 
 
1 p.R12* Hepatocerebral 42 d 
 
[38] 
c.130G>A 1 
 
p.E44K Hepatocerebral 4 mo [53] 
c.137A>G 
 
1 p.N46S Hepatic Alive [32] 
c.143-309_170del335  
 
Intron 1 p.A48fs*90 Hepatocerebral 12 mo [54] 
c.155C>T 2 p.S52F Hepatocerebral Alive
 
 
 
[34] 
 
c.223T>A 
 
2 p.W75R Hepatocerebral 8-11mo [55] 
c.235C>T 
 
2 p.Q79* Hepatocerebral 4-5 mo [33] 
c.255delA 2 p.A86Pfs*13 
 
Hepatocerebral ≤ 12 mo [6] 
c.313C>T 3 p.R105* 
 
Hepatocerebral 5 mo [40] 
[32] 
c.318G>A 
 
3 p.S107* Hepatocerebral
 
3 mo [33] 
c.319T>C 3 p.S107P Hepatic Alive [7] 
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(3.5 yo) 
 
 
c.352C>T 3 p.R118C Hepatocerebral 9 mo [56] 
 
c.444-62C>A Intron 3 p. D147_R148ins20 
 
Hepatocerebral 14-18  mo 
 
[44] 
 
c.493G>A 
 
4 p.E165K Hepatocerebral 11 mo [53] 
c.494A>T 4 p.E165V Hepatocerebral 2.5 mo [39] 
 
c.533G>A 4 p.W178* Hepatocerebral 12-15 mo
¤
 [7, 46] 
 
 
c.572A>G 4 p.Y191C Hepatic 44 d [47] 
 
c.592-4_592-3delTT 
 
Intron 4 p.Q197_L237del 
 
Hepatocerebral 6 mo [42] 
c.609_610delGT 5 p.Y204Pfs*11 Hepatocerebral 6 mo 
 
[37] 
c.617G>A 
 
5 p.R206K Hepatocerebral 12 mo [55] 
c.677A>G 5 p.H226R Hepatocerebral 1-8 mo 
 
[45, 57]  
 
c.707+3_6delTAAG 
 
Intron 5 p.(T235fs*9) Hepatocerebral  [53] 
c.707+417_834+3416del Intron 5 p. K236_L277del Hepatocerebral 6.5 mo [41] 
      
c.ins721_724TGAT 
 
6 p.N253* Hepatocerebral 4 mo [32] 
c.749T>C 6 p.L250S Hepatocerebral 24 mo  [31, 45, 58, 59]
¤
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 or alive 
 
[32] 
 
c.763G>T 
 
6 p.D255Y Hepatic
 ¤
 Alive [60] 
c.763_766dupGATT 6 p.F256* Hepatocerebral 
 
Hepatic 
 
 
 
 
 
1-31 mo 
 
 
 
 
 
 
 
[43] 
[61] 
[36] 
[57] 
[39] 
[37] 
[48] 
[55] 
 
c.765_769insTGAT 6 p.F256* 
 
Hepatocerebral 4 mo [31] 
 
¤ liver transplantation; d, days; mo, months; yo, years old.  
NOTE: alive refers to patient alive at the time of the report publication.
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Table 2. Heterozygous mutations in the DGUOK gene associated with hepatocerebral and hepatic forms of MDS. 
Mutation Location 
Exon/ 
Intron 
Effect Autosomal 
Inheritance 
Clinical 
phenotype 
Survival Reference 
c.1A>G 
c.3G>A 
1 
1 
 
p.M1? 
p.M1? 
Compound heterozygous Hepatic Alive
¤
 [34] 
 
c.143-309_170del335  
c.743T>C 
 
Intron 1 
 
 
6 
p.A48fs*90 
 
 
p.L248P 
Compound heterozygous Hepatocerebral 12 mo [54] 
c.155C>T 
c.681_684delGTTT 
 
2 
5 
p.S52F 
p.E228Gfs*14 
Compound heterozygous Hepatocerebral 13 mo [34] 
c.749T>C 
c.2T>C
§
 
6 
1 
p.L250S 
p.M1? 
Compound heterozygous Hepatocerebral 
Hepatic 
 
9 mo 
Alive 
[34] 
 
c.509A→G 4 p.Q170R Heterozygous Hepatocerebral 
 
Alive [34] 
 
c.137A>G 
c.797T>G 
1 
6 
p.N46S 
p.L266R 
 
Compound heterozygous Hepatic Alive [36] 
 
c.4G>T 
c.142+1G>A 
c.591G>A 
1 
Intron 1 
4 
p.A2S 
p.0 
p.Q197= 
 
Compound heterozygous Hepatocerebral 3 mo [36]   
c.3G>A 
c.813_814insTTT 
1 
7 
p.M1? 
p.N271_T272insF 
Compound heterozygous Hepatocerebral 6.5 mo [39] 
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c.425G>A 
c.679G>A 
3 
5 
p.R142K 
p.E227K 
 
Compound heterozygous Hepatic Alive [37] 
c.632A>G 
c.797T>G 
5 
6 
p.E211G 
p.L266R 
 
Compound heterozygous Hepatic 9 mo [31] 
c.494A>T 
c.797T>G 
 
4 
6 
p.E165V 
p.L266R 
Compound heterozygous Hepatic 18 mo 
 
[31] 
[32] 
c.81delC 
c.763_766dupGATT 
1 
6 
p.S28Pfs*28 
 p.F256* 
 
Compound heterozygous Hepatocerebral 6 mo [7] 
 
 
c.487_490insGACA 
c.195G>A 
4 
2 
 
p.R142Vfs*5 
p.W65* 
Compound heterozygous Hepatocerebral 7-12 mo 
 
[7] 
 
 
c.605_606delGA 
 c.591G>A 
 
5 
4 
p.R202Tfs*13 
p.Q197= 
Compound heterozygous Hepatocerebral 23 mo [7] 
c.572A>G 
c.151A>C 
 
4 
2 
p.Y191C 
p.K51Q 
Compound heterozygous Hepatocerebral 
 
8 mo [7] 
c.137A>G 
c.352C>T  
1 
3 
 
p.N46S 
p.R118C 
 
Compound heterozygous Hepatic Alive [7] 
c.592-4_592-3delTT 
c.677A>G 
 
Intron 4 
5 
p.Q197_L237del 
p.H226R 
Compound heterozygous Hepatocerebral 8 mo [7] 
c.605_606delGA 
c.444-11C>G 
 
5 
Intron 3 
p.R202Tfs*13 
p.0 
Compound heterozygous Hepatocerebral 7 mo [7] 
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c.679G>A 
c.444_591del 
 
5 
4 
p.E227K 
p.R148_V198del 
Compound heterozygous Hepatocerebral Alive 
(4 mo) 
[62] 
c.591G>A 
c.424_425delAG 
 
4 
3 
p.Q197= 
p.R142Vfs*5 
Compound heterozygous Hepatocerebral Alive [32] 
c.256-2A>C 
c.749T>C 
 
Intron 2 
6 
p.(K85_S91fs*36) 
p.L250S 
Compound heterozygous Hepatocerebral 10 mo [32] 
c. 494A>T 
c.737C>G 
4 
6 
p.E165V 
p.P246R 
 
Compound heterozygous Hepatic Alive [32] 
* Hepatopathy comprises liver enlargement, cholestasis, hepatic cytolysis and liver failure. Central nervous systems cardinal symptoms are 
hypotonia, nystagmus and/or psychomotor retardation, ¤ liver transplantation, 
§ mutation detected in two siblings, ξ cerebral symptoms 
(nistagmus) only develops after liver transplantation, ¤ previously identified [34] but as benign compound heterozygous. mo, months. 
NOTE: alive refers to patient alive at the time of the report publication. 
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ADULT PATIENTS CARRYING DGUOK MUTATIONS 
 
For many years, DGUOK deficiency was thought to cause exclusively hepatic and 
cerebral disease in children. However, two recent reports showed that mutations in the 
DGUOK genes can lead to a myopathic form of MDS in adulthood [50, 63].  
Patients were diagnosed with myopathy at ages varying from 20 to 69 years old. They 
had chronic muscular fatigue, myalgia, dysphagia, dysphonia, ptosis and/or progressive 
external ophthalmoplegia. Liver symptoms were not observed. Muscle biopsies revealed 
significant decrease of mtDNA load (although not as severe as the depletion degree observed 
in pediatric patients) and some presented ragged red fibers. Found mutations were all in 
compound heterozygosity (table 3) and, as observed for hepatic patients, both allelic variants 
were of missense type with one of them being pathogenic, as computationally predicted or 
reported in patients [32, 34, 36]. The reason why these patients did not develop a neonatal 
hepatocerebral or hepatic phenotype is unknown. However it is conceivable that some of the 
DGUOK activity is preserved in these patients, capable of sustaining demanding nucleotides 
synthesis in early life. Since mtDNA replication rate decreases with age, even low levels of 
DGUOK activity may be sufficient to prevent liver and cerebral disease. Muscle involvement 
in these patients may be due to prolonged exposure of muscle fibres to low DGUOK activity, 
resulting in myopathy in adulthood.   
Myopathic phenotype in DGUOK patients highlights the complex and multi-systemic 
range mutations this gene can have and the importance of screening patients with 
mitochondrial disease for all genes known to be involved in mitochondria biosynthesis and 
function. 
Duarte S., 2014 
 
23 
 
Table 3. Mutations in the DGUOK gene associated with the myopathic form of MDS. 
Mutation Effect Autosomal 
Inheritance 
Age of 
diagnosis 
Reference 
c.81_82insCC 
c.4G>T  
 
p.P28Sfs*57p.A2S 
p.A2S 
Compound 
heterozygous 
21 yo [63] 
c.605_606delGA 
c.462T>A 
p.R202Yfs*12 
p.N154K 
 
Compound 
heterozygous 
58 yo [50] 
c.130G>A 
c.462T>A 
p.E44K 
p.N154K 
 
Compound 
heterozygous 
46 yo [50] 
c.186C>A 
c.509A>G 
 
p.Y62X 
p.Q170R 
Compound 
heterozygous 
69 yo [50] 
c.605_606delGA 
c.137A>G 
p.R202Yfs*12 
p.N46S 
 
Compound 
heterozygous 
20 yo [50] 
c.444-11 C>G§ 
c.509>G  
p.0 
p.Q170R 
Compound 
heterozygous 
 
40 yo [50] 
c.444-11 C>G§ 
c.509A>G  
p.0 
p.Q170R 
Compound 
heterozygous 
 
44 yo [50] 
     
yo, years old. § siblings 
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CONCLUSION 
 
Given the complexity of DGUOK associated mitochondrial disorders, it is difficult to 
establish a strict relation between the genotype and phenotype, which would allow the 
prediction of the severity and course of the disease in individual patients. 
It is clear that missense mutations are associated to a milder phenotype and that 
compound heterozygous have better chance of developing childhood non fatal isolated 
hepatic or even myopathic, adult onset, disease. 
Homozygous mutations are, in most cases, associated with a worse prognosis.  
The capability to predict the clinical phenotype at a prenatal stage would be of great 
value for genetic counselling. 
Thus, further studies are required to understand the pathogenesis of the mutations 
underlying MDS disorders.  
MDS spectrum diseases, associated with DGUOK deficiency, are clinically very 
heterogeneous and since the enzyme is ubiquitously expressed; theoretically, all tissues can be 
affected. Tissues in which it is expressed at higher levels, such as liver and brain [28], are 
frequently severely affected. However, as damage from low enzymatic activity accumulates 
and mtDNA depletion aggravates, other organs may be involved, such as skeletal muscle and 
heart. Therefore, it is important to screen for DGUOK mutations both in infants and in adults 
suffering from mitochondrial disease, particularly if the liver is affected. 
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MATERIALS AND METHODS 
 
A comprehensive search on MEDLINE (via PubMed) database of references for peer-
reviewed literature of DGUOK-deficiency-associated-MDS was performed using the 
following keywords: “DGUOK”, “dGK”, “DGUOK mutation”, “mitochondrial depletion 
syndrome” and “hepatocerebral”. No language or date of publication restrictions were 
applied.  
All the articles considered to be relevant were analysed for the methodological 
accuracy in the molecular study of DGUOK mutations. 
A systematic summary of the findings from the different studies, in the form of easy-
to-consult tables was elaborated, where a genotype-phenotype correlation is established for 
each published mutation in DGUOK gene. Data withdrawal was double-checked by four 
collaborators and disagreements discussed between them and the review authors. 
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